Ohio introduced a legalization bill, cannabis and psilocybin could be the future of cancer care, and a ketamine company is looking to take the lead in the space.
Let’s dive into this week’s canna-news.
Ohio Eyes Legalization With HB 168
Ohio is inching closer to making cannabis legalization a reality. The bipartisan-backed House Bill 168—the Ohio Adult Use Act—is looking to legalize the cultivation, purchase, and possession of cannabis for individuals aged 21 and older. If passed, the bill would also expunge the records of those convicted on cultivation and possession charges.
HB 168 includes a 10% sales tax on recreational cannabis purchases. According to researchers at Ohio State University, the sales tax could help generate up to $374 million for the state in the first 5 years of operation.
Lastly, HB 168 also proposes some changes to Ohio’s current Medical Marijuana Control Program, starting with a rebrand. The office will be renamed to the Division of Marijuana Control. The renamed division will be tasked with overseeing the new recreational market and its associated programs should the bill pass.
What do you think of the push for legalization going on in Ohio? Let us know in the comments!
Apply For Your Medical Marijuana Card Today
-
Veriheal has satisfied hundreds of thousands of patients nationwide - Get approved or your money back
- Appointments available on-demand
- Customer support available 24/7
CaaMTech Rethinks the Future of Cancer Care
Washington-based cannabinoid laboratory CaaMTech is looking to revolutionize the future of cancer care with psilocybin and cannabis. The company is currently conducting research on how these substances interact and complement each other. Researchers hope to find the ratio of cannabis and psilocybin that maximizes each substance’s benefits.
There is growing anecdotal evidence showing just how effectively cannabis and psilocybin can treat folks with cancer. Most recently, a 49-year-old woman experienced a noticeable reduction in the size of her tumor after taking cannabis and psilocybin together. The woman’s results, along with other similar cases, indicate that the combo may be effective in reducing tumor inflammation while reducing the psychological distress experienced by many during chemotherapy.
What do you think of CaaMTech’s ambitious research endeavor? Do you think cannabis and psilocybin are the future of cannabis care? Let us know in the comments!
Ketamine Company Continues Expansion
As ketamine continues to gain legitimacy as an alternative medicine, one company is ramping up to become a leader in the space.
Chose Ketamine is a wellness platform offering at-home ketamine therapy. The company recently extended its service area to include Arizona, Connecticut, Georgia, and Michigan. With this expansion, Choose Ketamine can now help an additional 31.7 million Americans get the help they need. As a whole, Choose Ketamine now serves over 50% of the U.S. population!
Next up, Choose Ketamine is looking to expand into Oregon, Pennsylvania, New York, and Tennessee.
